Sells nerve grafts and other products surgeons and healthcare providers use to repair and protect peripheral nerves.
10-K for FY2025, filed Feb 24, 2026We are the leading company focused specifically on the science, development, and commercialization of technologies for peripheral nerve…View ↗
Avance® Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the…View ↗
To improve the options available for the surgical repair and regeneration of peripheral nerves, we have developed and licensed regenerative…View ↗
Hospitals and surgical facilities pay for nerve-repair products, with payment typically due in full within 30 days of delivery. For products held at hospitals or by sales agents, the sale is counted when the product is used or implanted.
10-K for FY2025, filed Feb 24, 2026The Company enters into contracts to sell and distribute products and services to hospitals and surgical facilities for use in caring for…View ↗
A portion of the Company’s product revenue is generated from consigned inventory maintained at hospitals and independent sales agencies…View ↗
The contract with the customer states the final terms of the sale, including the description, quantity, and price of each implant…View ↗
$225.2M
10-K for FY2025, filed Feb 24, 2026
$225.2M ↗
Hospitals and surgical facilities buy products for patient care; international distributors buy implants for resale in contract-defined territories.
10-K for FY2025, filed Feb 24, 2026
No. It lost $15.7M in FY2025.
8-K, filed Oct 28, 2026
For 2026, we expect full-year revenue of at least $290 million, representing growth of at least 29%, including at least $7 million revenue…View ↗
8-K, filed Oct 1, 2026
The Company expects BioCircuit to contribute approximately $6 million to fourth-quarter 2026 and approximately $34 million to 2027 revenue.…View ↗
Growing. Revenue grew 77% in 4 years, from $127.4M in FY2021 to $225.2M in FY2025, about 15% a year.
Expands breast reconstruction use
The breast offering has expanded from autologous-flap reconstruction to include implant-based procedures using Resensation.
10-K for FY2022, filed Mar 14, 2023 10-K for FY2025, filed Feb 24, 2026We estimate that the Breast portion of the Total Addressable Market is approximately $250 million. Currently, when a patient undergoes…View ↗
We previously estimated the breast portion of the TAM based on autologous flap reconstructions (i.e. DIEP flaps) and presently believe it…View ↗
Adds urology to current revenue markets
The older report described urology as a possible market expansion; the latest report includes urology among the areas generating primary revenue.
10-K for FY2022, filed Mar 14, 2023 10-K for FY2025, filed Feb 24, 2026Although distribution and sales of products in the Trauma, OMF, Breast and Upper Extremity Compression portions of the Total Addressable…View ↗
Although distribution and sales of products in the extremities, oral maxillofacial and head and neck, breast and urology portions of the…View ↗
Adds a soft-tissue product
The older report says Avive Soft Tissue Membrane was suspended from market availability; the latest report lists Avive+ Soft Tissue Matrix and says it launched.
10-K for FY2022, filed Mar 14, 2023 10-K for FY2025, filed Feb 24, 2026We suspended the market availability of Avive® Soft Tissue Membrane ("Avive") effective June 1, 2021 and we continue discussions with the…View ↗
Loading...